Intra-arterial nitroglycerin as directed acute treatment in experimental ischemic stroke
- 19 December 2016
- journal article
- research article
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 10 (1) , 29-33
Abstract
Background Nitroglycerin (also known as glyceryl trinitrate (GTN)), a vasodilator best known for treatment of ischemic heart disease, has also been investigated for its potential therapeutic benefit in ischemic stroke. The completed Efficacy of Nitric Oxide in Stroke trial suggested that GTN has therapeutic benefit with acute (within 6 hours) transdermal systemic sustained release therapy. Objective To examine an alternative use of GTN as an acute therapy for ischemic stroke following successful recanalization. Methods We administered GTN IA following transient middle cerebral artery occlusion in mice. Because no standard dose of GTN is available following emergent large vessel occlusion, we performed a dose–response (3.12, 6.25, 12.5, and 25 µg/µL) analysis. Next, we looked at blood perfusion (flow) through the middle cerebral artery using laser Doppler flowmetry. Functional outcomes, including forced motor movement rotor rod, were assessed in the 3.12, 6.25, and 12.5 µg/µL groups. Histological analysis was performed using cresyl violet for infarct volume, and glial fibrillary activating protein (GFAP) and NeuN immunohistochemistry for astrocyte activation and mature neuron survival, respectively. Results Overall, we found that acute post-stroke IA GTN had little effect on vessel dilatation after 15 min. Functional analysis showed a significant difference between GTN (3.12 and 6.25 µg/µL) and control at post-stroke day 1. Histological measures showed a significant reduction in infarct volume and GFAP immunoreactivity and a significant increase in NeuN. Conclusions These results demonstrate that acute IA GTN is neuroprotective in experimental ischemic stroke and warrants further study as a potentially new stroke therapy.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (3R01NS065842-08S1)
This publication has 19 references indexed in Scilit:
- Effect of Hyperacute Administration (Within 6 Hours) of Transdermal Glyceryl Trinitrate, a Nitric Oxide Donor, on Outcome After StrokeStroke, 2015
- Statistical Analysis Plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) TrialInternational Journal of Stroke, 2014
- Statistical Analysis Plan for the ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) TrialInternational Journal of Stroke, 2014
- Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010The Lancet, 2014
- Nitric Oxide Donors as Neuroprotective Agents after an Ischemic Stroke-Related Inflammatory ReactionOxidative Medicine and Cellular Longevity, 2013
- Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trialThe Lancet, 2012
- Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodentsJournal of Clinical Investigation, 2011
- Vascular nitric oxide: formation and functionJournal of Blood Medicine, 2010
- A rapid, simple, and humane method for submandibular bleeding of mice using a lancetLab Animal, 2005
- Nitric oxide in acute ischaemic stroke: a target for neuroprotectionJournal of Neurology, Neurosurgery & Psychiatry, 1999